Search ARM

Enzyvant is a biopharmaceutical company dedicated to developing breakthrough biotechnologies and transformative therapies for people with devastating rare diseases. The Enzyvant pipeline includes investigational regenerative therapies for T-cell implicated conditions and enzyme therapies for acid ceramidase deficiency. Enzyvant investigational therapies have been granted numerous regulatory designations in the U.S. and Europe, including Breakthrough Therapy (BTD) and Regenerative Medicine Advanced Therapy (RMAT). Enzyvant is part of Sumitovant Biopharma, a wholly owned subsidiary of Sumitomo Dainippon Pharma Co. (DSP), which was formed in December 2019 by a strategic alliance between Roivant Sciences, Ltd. and DSP. People with rare diseases are fighting for their lives. Enzyvant is dedicated to helping patients win that fight. Visit to learn more. 

Contact Enzyvant Therapeutics
+1 617 704 9385
Visit Website